eFFECTOR is pioneering the field of Selective Translation Regulator Inhibitors(STRIs)
Transcription is the copying of DNA sequences into mRNA, whereas translation is the subsequent utilization of mRNA sequences to direct protein synthesis. While the regulation of transcription is widely recognized, eFFECTOR is pioneering the field of Selective Translation Regulator Inhibitors (STRIs).
Regulation of transcription
Regulation of translation
eFFECTOR’s translation regulation targets are downstream of key signaling pathways and impact multiple complementary cancer growth and survival mechanisms.
The importance of translation regulation in disease is becoming increasingly recognized in the pharmaceutical industry, and we believe we are at the forefront of discovering novel approaches to cancer therapy focused on STRIs. Utilizing our proprietary selective translation regulation technology platform and expertise, we have developed an understanding of genes that are translationally dysregulated in multiple tumor types. This has enabled us to identify specific points of therapeutic intervention that may have a meaningful clinical effect.
Inflammation Tumor Promotion
Resisting Cell Death
Our programs target three distinct targets in the eIF4F translation initiation complex: MNK 1/2, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.
Key regulation points for potent biological processes
Downstream from multiple oncogenes
Upstream from key cancer driving processes
Terminal node in key signaling pathways limits resistance mechanisms
Each target regulates a distinct cancer gene set
11120 Roselle Street, Suite A
San Diego, CA 92121